Dark Forest Capital Management LP Buys Shares of 15,575 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Dark Forest Capital Management LP bought a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 15,575 shares of the company's stock, valued at approximately $536,000.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Harmony Biosciences by 36.4% during the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after purchasing an additional 1,262,362 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Harmony Biosciences by 165.2% during the fourth quarter. Marshall Wace LLP now owns 929,744 shares of the company's stock valued at $31,992,000 after purchasing an additional 579,103 shares during the last quarter. Norges Bank purchased a new position in shares of Harmony Biosciences during the fourth quarter valued at approximately $16,118,000. Pacer Advisors Inc. grew its position in Harmony Biosciences by 18.2% during the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after buying an additional 351,582 shares during the period. Finally, Invesco Ltd. grew its position in Harmony Biosciences by 173.9% during the fourth quarter. Invesco Ltd. now owns 449,180 shares of the company's stock valued at $15,456,000 after buying an additional 285,156 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY traded up $0.23 during midday trading on Thursday, reaching $29.70. 210,693 shares of the company were exchanged, compared to its average volume of 572,351. The stock has a market cap of $1.70 billion, a PE ratio of 14.11, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80. The business's fifty day moving average is $31.63 and its two-hundred day moving average is $34.16. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.11. The company had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences's revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 earnings per share. As a group, analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

HRMY has been the subject of several recent research reports. UBS Group cut their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Needham & Company LLC reiterated a "buy" rating and issued a $50.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Finally, Mizuho upped their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 18th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $52.44.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.